BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

...Inc. CNM-Au8 Orally administered nanocrystalline gold suspension NA Neuroprotection Implicit Biosciences Ltd. IC14 mAb against CD14...
...and failed to pinpoint specific inflammatory pathways altered in ALS. IC14 is a mAB against CD14... release pro-inflammatory cytokines. Implicit hypothesizes that inhibition of CD14 will turn off hyperactivation of CD14...
BioCentury | Sep 27, 2019
Product Development

Lessons from Healey ALS on how to build platform trials quickly

...Inc. CNM-Au8 Orally administered nanocrystalline gold suspension NA Neuroprotection Implicit Biosciences Ltd. IC14 mAb against CD14...
BioCentury | May 1, 2019
Translation in Brief

White matter matters in Alzheimer’s

...promotes axon and dendrite outgrowth, was an AD marker in excitatory neurons; and C1QB and CD14...
...repeat and Ig domain containing 1; NTNG1 - Netrin G1 Sandi Wong, Staff Writer Massachusetts Institute of Technology CD14 Leucine...
BioCentury | Sep 28, 2018
Tools & Techniques

Deconstructing tox in immuno-oncology incorporate human myeloid cells into mouse models since cancers like melanoma are dominated by CD14-positive...
BioCentury | Oct 24, 2016
Product Development

A new BEAT for AML

...ASH presentations Array BioPharma Inc. (NASDAQ:ARRY) ARRY-382 Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115) inhibitor CD14/CSF1R-positive...
...Ltd. (Tokyo:4568) Quizartinib FLT3 inhibitor FLT3-positive Ph III GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) GW2580 CSF1R inhibitor CD14/CSF1R-positive...
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: Inositol polyphosphate-4-phosphatase type II (INPP4B); phosphatase and tensin homolog deleted on chromosome ten (PTEN; MMAC1; TEP1)

Cancer INDICATION: Thyroid cancer Mouse and human sample studies suggest agonizing INPP4B could help treat PTEN-deficient thyroid cancer. INPP4B levels were lower in thyroid tissues samples from thyroid cancer patients than in samples from control...
BioCentury | Feb 26, 2015
Distillery Techniques

Techniques: Mesenchymal stem cell (MSC) screen for oncogenic drivers of undifferentiated sarcomas

Disease models TECHNOLOGY: Cell models An MSC model could help identify therapeutics to treat undifferentiated sarcomas. In isolated MSC-enriched mouse bone marrow cells, p53 depletion plus expression of known sarcoma oncogenes induced sarcomagenesis. In p53-deficient...
BioCentury | Jan 29, 2015
Distillery Therapeutics

Therapeutics: EPH receptor A2 (EPHA2); BRAF

Cancer INDICATION: Melanoma Cell culture, mouse and patient studies suggest inhibiting EPHA2 could help treat melanoma that is resistant to the BRAF inhibitor Zelboraf vemurafenib. In metastatic lesions from melanoma patients on Zelboraf therapy, EPHA2...
BioCentury | Jan 8, 2015
Distillery Therapeutics

Therapeutics: Notch 1 (NOTCH1); jagged 1 (JAG1); jagged 2 (JAG2)

Cancer INDICATION: Cancer In vitro and mouse studies suggest inhibiting JAG-mediated NOTCH1 signaling could help treat cancer by inhibiting angiogenesis. In an in vitro angiogenesis assay, human endothelial cells expressing NOTCH1 decoy proteins that inhibited...
BioCentury | Nov 6, 2014
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mutant neuroblastoma Ras viral (v-Ras) oncogene (Nras) mouse model of melanoma Mice expressing activating mutations in Nras could help identify new treatments for melanoma. The...
Items per page:
1 - 10 of 36